reverse-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-06. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
| Property | Value | Notes |
|---|---|---|
| Water content | Low in freshly lyophilised material | Rises after repeated opening of the same vial |
| Solution stability | Lower than powder stability | Frozen aliquots are preferred over repeated thawing |
| Purity assessment | Reversed-phase HPLC with UV detection | Peak-area percentage excludes salts and water |
| Salt form | Often the trifluoroacetate salt | Retained from acidic purification gradients |
| Light sensitivity | Not strongly photoreactive | Dark storage still advised for long-term keeping |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
=== Neuroadaptation and sensitization === Reward sensitization is a process that causes an increase in the amount of reward (specifically, incentive salience) that is assigned by the brain to a rewarding stimulus (e.g., a drug). In simple terms, when reward sensitization to a specific stimulus (e.g., a drug) occurs, an individual's "wanting" or desire for the stimulus itself and its associated cues increases. Reward sensitization normally occurs following chronically high levels of exposure to the stimulus. On the incentive-sensitization account, "cue-induced wanting" or "cue-triggered wanting" – a form of craving triggered by drug-associated cues – drives much of the compulsive behavior seen in addiction. During the development of an addiction, the repeated association of otherwise neutral and even non-rewarding stimuli with drug consumption triggers an associative learning process that causes these previously neutral stimuli to act as conditioned positive reinforcers of addictive drug use (i.e., these stimuli start to function as drug cues). As conditioned positive reinforcers of drug use, these previously neutral stimuli are assigned incentive salience (which manifests as a craving) – sometimes at pathologically high levels due to reward sensitization – which can transfer to the primary reinforcer (e.g., the use of an addictive drug) with which it was originally paired. Incentive sensitization is one of several competing accounts of addiction.
== History and literature == The compound was discovered by Justus von Liebig and Friedrich Wöhler. It is one of the oldest named organic compounds. It was originally prepared in 1818 by Luigi Valentino Brugnatelli (1761-1818) and was named in 1838 by Wöhler and Liebig. The name "Alloxan" emerged from an amalgamation of the words "Allantoïn" and "Oxalsäure" (oxalic acid). The alloxan model of diabetes was first described in rabbits by Dunn, Sheehan, and McLetchie in 1943. The name is derived from allantoin, a product of uric acid excreted by the fetus into the allantois, and oxaluric acid derived from oxalic acid and urea, found in urine. Alloxan was used in the production of the purple dye murexide, discovered by Carl Wilhelm Scheele in 1776. Murexide is the product of the complex in-situ multistep reaction of alloxantin and gaseous ammonia. Murexide results from the condensation of the unisolated intermediate uramil with alloxan liberated during the course of the reaction.
The New Zealand-founded and California-based Rocket Lab had recently acquired the Arizona company Geost, which is involved in the Golden Dome project. Russia: Russian Foreign Ministry spokeswoman Maria Zakharova said "the United States' Golden Dome project undermines the foundations of strategic stability as it involves the creation of a global missile defense system." On 8 May 2025, China and Russia made a joint statement criticizing the proposal's rejection of the "inseparable interrelationship between strategic offensive arms and strategic defensive arms", its "left-of-launch" capabilities, and its "orbital deployment of interception systems". On 21 May 2025, Press Secretary Dmitry Peskov instead stated that the plan was a "sovereign matter" for the US, and that the legal framework of defunct US-Russia nuclear arms treaties "must be recreated both in the interests of our two countries and in the interests of security throughout the planet". North Korea: On 27 May 2025, North Korea's Ministry of Foreign Affairs criticized the proposal as representing "an outer space nuclear war scenario". It denounced "undisguised moves for space militarization" and argued regional stability requires "the symmetry of the matchless power".
== Mechanism of action == Ipglycermides bind at the interface of the iPGM phosphotransferase and phosphatase domains as revealed in several co-crystal structures obtained with C. elegans (5KGN, 7KNF, 7KNG, 7TL7) and Staphylococcus aureus (7TL8) iPGMs and a variety of ipglycermides. Lariate ipglycermides containing either a terminal cysteine or hydroxamic acid have sub-nanomolar affinity for C. elegans iPGM, while truncated analogs, such as ipglycermide Ce-2d bind potently in the low nanomolar range.
Sources: en.wikipedia.org
The dissolution of collagen depends on time, temperature, and environmental pH. At high temperatures, the rate of collagen loss will be accelerated, and extreme pH can cause collagen swelling and accelerated hydrolysis. Due to the increase in porosity of bones through collagen loss, the bone becomes susceptible to hydrolytic infiltration where the hydroxyapatite, with its affinity for amino acids, permits charged species of endogenous and exogenous origin to take up residence. The hydrolytic activity plays a key role in the mineral phase transformations that expose the collagen to accelerated chemical- and bio-degradation. Chemical changes affect crystallinity. Mechanisms of chemical change, such as the uptake of F− or CO2−3 may cause recrystallization where hydroxyapatite is dissolved and re-precipitated allowing for the incorporation or substitution of exogenous material. Once an individual has been interred, microbial attack, the most common mechanism of bone deterioration, occurs rapidly. During this phase, most bone collagen is lost and porosity is increased. The dissolution of the mineral phase caused by low pH permits access to the collagen by extracellular microbial enzymes thus microbial attack.
== Function == Glutamate cysteine ligase (GCL) catalyzes the first and rate-limiting step in the production of the cellular antioxidant glutathione (GSH), involving the ATP-dependent condensation of cysteine and glutamate to form the dipeptide gamma-glutamylcysteine (γ-GC). This peptide coupling is unique in that it occurs between the amino moiety of the cysteine and the terminal carboxylic acid of the glutamate side chain (hence the name gamma-glutamyl cysteine). This peptide bond is resistant to cleavage by cellular peptidases and requires a specialized enzyme, gamma-glutamyl transpeptidase (γGT), to metabolize γ-GC and GSH into its constituent amino acids. GCL enzymatic activity generally dictates cellular GSH levels and GSH biosynthetic capacity. GCL enzymatic activity is influenced by numerous factors, including cellular expression of the GCL subunit proteins, access to substrates (cysteine is typically limiting in the production of γ-GC), the degree of negative feedback inhibition by GSH, and functionally relevant post-translational modifications to specific sites on the GCL subunits. Given its status as the rate-limiting enzyme in GSH biosynthesis, changes in GCL activity directly equate to changes in cellular GSH biosynthetic capacity. Therefore, therapeutic strategies to alter GSH production have focused on this enzyme.
The new republican regime, however, did not fare well in the Mezzogiorno, especially in Calabria, where only Cosenza, Catanzaro and Crotone adhered to the republican cause, while the large Ionian centers and the area opposite the Sicilian coast, such as Reggio Calabria, Scilla, Bagnara and Palmi, remained loyal to the Bourbons. The Bourbon royals, in exile in Palermo expected that they would be able to regain the kingdom. Ferdinand gladly accepted Cardinal Fabrizio Ruffo's proposal to mobilize the peasant masses of Calabria under the name of the king and religion, form an army and recapture Naples. Having received, on 7 February 1799, the title of “Vicar of the King”, Cardinal Ruffo landed the next day in Calabria, recruiting among the family fiefs of Scilla and Bagnara. Soon Ruffo's army, dubbed the Army of the Holy Faith, marched under the banners of the Church and the throne. It grew to 25,000 men, to which were added bands of brigands, stragglers, and deserters. The cardinal succeeded in conquering and sacking Paola and Crotone, despite Ruffo's attempts to prevent the looting and violence. In four months it reconquered the Kingdom of Naples. He granted in June 1799 an honorable surrender to the last Neapolitan Jacobins barricaded at Fort Saint Elmo. However, this was not respected by the Bourbon rulers or Admiral Horatio Nelson, who, reneged and hanged 124 Neapolitan revolutionaries, depriving Ruffo of his command.
The American Expedition (1799–1804) was a scientific exploration of Spanish America conducted by the Prussian naturalist Alexander von Humboldt and the French botanist Aimé Bonpland. Over the course of five years, the expedition traversed across present-day Venezuela, Colombia, Ecuador, Peru, Cuba, Mexico, and parts of the United States. Humboldt and Bonpland conducted pioneering research in fields including geography, biology, geology, meteorology, and ethnography. They observed and described vast regions of South and Central America, mapping rivers like the Orinoco and investigating the Andes Mountains—including an attempt to climb Chimborazo, accompanied by local savants and informants. Their observations of plant and animal life, atmospheric phenomena, and indigenous cultures - influenced by the debates ongoing in Spanish American in those years - laid the foundations for modern biogeography and ecology.
== Treatment == There are two different main mechanism of treatment for toxification with AzM. One possibility is to treat the patient before exposure to AzM and the other one is to treat the patient after poisoning. Competitive antagonists of AChE can be used for pre-treatment. They can reduce mortality, which is caused by exposure to AzM. Organophosphorus AChE inhibitors can bind temporally to the catalytic site of the enzyme. Because of this binding, AzM cannot phosphorylate the enzyme anymore and the enzyme is shorter inhibited. The mechanism for treatment after exposure is to block the muscarinic receptor activation. Anticonvulsants are used to control the seizures and oximes are used to reactivate the inhibited AChE. Oximes remove the phosphoryl group bound to the active site of the AChE by binding to it. There are a few oximes that are the most efficacious by AzM poisoning, namely oxime K-27 and physostigmine. These two treatments are also used together, some patients are namely treated with atropine (a competitive antagonist of AChE) and reactivating oximes. When patients are resistant to atropine, the patients can be treated with low doses of anisodamine, a cholinergic and alpha-1 adrenergic antagonist, to achieve a shorter recovery time. Treatment with a combination of different alkaloids or synergistically with atropine is safer than using high antroponine concentrations, which can be toxic. Another possibility is to use membrane bioreactor technology. When this technology is used, no other chemical compounds need to be added.
Sources: en.wikipedia.org
Pfizer Inc. ( FY-zər) is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America. Pfizer develops and produces medication and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company's largest products by sales are Eliquis (apixaban) ($7.9 billion in 2025 revenues, 13% of total revenues), Prevnar (a pneumococcal conjugate vaccine) ($6.5 billion in 2025 revenues, 10% of total revenues), Paxlovid (Nirmatrelvir/ritonavir) ($2.4 billion in 2025 revenues, 4% of total revenues), Vyndaqel (tafamidis) ($6.4 billion in 2025 revenues, 10% of total revenues), Comirnaty (the Pfizer–BioNTech COVID-19 vaccine) ($4.4 billion in 2025 revenues, 7% of total revenues), and Ibrance (palbociclib) ($4.1 billion in 2025 revenues, 7% of total revenues). In 2025, 59% of the company's revenues came from the United States, 5% came from China, and 36% came from other countries. The company is ranked fifth on the list of largest biomedical companies by revenue. It is ranked the 69th on the Fortune 500 and 73rd on the Forbes Global 2000.
== Personal life == Kiggans is a lifelong Roman Catholic. She has been married since 1999 to Steve Kiggans, a retired Navy F-18 pilot. They have four children. Kiggans' father is also a veteran, serving in the Vietnam War as an Army Green Beret.
=== Reign of Doomsday === Boodikka later appears at the remains of the destroyed planet New Krypton, where she encounters Batman and Supergirl. Boodikka explains that the Guardians had sent her on a mission to survey the ruins as a follow-up to the Green Lantern Corps' initial inspection of the planet. Suddenly, the heroes are attacked by Doomsday, who strikes Boodikka before she can react. Due to her injuries, Boodikka is unable to effectively wield her ring and is nearly captured by Doomsday before being rescued by Supergirl. With Starman and Saint Walker acting as a distraction, Batman and Supergirl take Boodikka to the JLA Watchtower. Doomsday follows the two aboard. As he's about to attack them, Cyborg Superman emerges from Boodikka's body. After Doomsday captures Supergirl and Cyborg Superman and flees the Watchtower, Starman states that Boodikka is healing herself in the Justice League's medical facility and should soon have enough energy to return to Oa. In War of the Green Lanterns, Boodikka and the Alpha Lanterns are killed by Alpha Lantern Varix and buried on Oa.
As of 2019, GSK-3 is the only type of glycogen synthase kinase named and recognized. The gene symbols for GSK1 and GSK2 have been withdrawn by the HUGO Gene Nomenclature Committee (HGNC), and no new names for these "genes" nor their locations have been specified.
== Mode of action == The molecular mechanism of inhibiting mechanosensitive channels by GsMTx-4 is bilayer-dependent. Rather than directly binding to the gating structures like other ICK peptides do, GsMTx4 makes the mechanosensitive channels less sensitive to mechanical tension of the bilayer membrane. By its tension-dependent insertion into the membrane, GsMTx4 is thought to distort the distribution of tension near mechanosensitive channels, which will make the transfer of force from the bilayer to the channel less efficient. Unlike other ICK peptides, the action of GsMTx-4 is not stereospecific, as both L- and D-GsMTx-4 can block MSCs.
Sources: en.wikipedia.org
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.
Mass spectrometry confirms identity, because the measured mass is compared with the value expected from the sequence. Chromatography mainly reports how much of the material elutes as the target peak.
It usually describes the share of the chromatographic peak area recorded at a set wavelength. Salts, residual water, and solvent are excluded from that number, so it is not the same as mass fraction.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.